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Background: New research criteria for the diagnosis of Alzheimer’s disease (AD) have recently been developed
to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers. To enable efficient
allocation of health care resources, evidence is needed to support decision makers on the adoption of emerging
biomarkers in clinical practice. The research goals are to 1) assess the diagnostic test accuracy of current clinical
diagnostic work-up and emerging biomarkers in MRI, PET and CSF, 2) perform a cost-consequence analysis
and 3) assess long-term cost-effectiveness by an economic model.
Methods/design: In a cohort design 241 consecutive patients suspected of having a primary neurodegenerative
disease are approached in four academic memory clinics and followed for two years. Clinical data and data on
quality of life, costs and emerging biomarkers are gathered.
Diagnostic test accuracy is determined by relating the clinical practice and new research criteria diagnoses to
a reference diagnosis. The clinical practice diagnosis at baseline is reflected by a consensus procedure among
experts using clinical information only (no biomarkers). The diagnosis based on the new research criteria is reflected
by decision rules that combine clinical and biomarker information. The reference diagnosis is determined by a
consensus procedure among experts based on clinical information on the course of symptoms over a two-year
time period.
A decision analytic model is built combining available evidence from different resources among which
(accuracy) results from the study, literature and expert opinion to assess long-term cost-effectiveness of the
emerging biomarkers.
Discussion: Several other multi-centre trials study the relative value of new biomarkers for early evaluation of AD
and related disorders. The uniqueness of this study is the assessment of resource utilization and quality of life to
enable an economic evaluation. The study results are generalizable to a population of patients who are referred
to a memory clinic due to their memory problems.
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Alzheimer’s disease (AD) and other dementing disorders
are common in the elderly, with a worldwide prevalence
estimated in 2010 at 35.6 million, which will double
every 20 years to 115.4 million in 2050. AD has a sub-
stantial impact on the person who suffers from the dis-
ease, his or her family and society [1]. AD affects a
person’s cognition, behavior and functional ability, and it
is one of the leading causes of disability in older people
living in developed countries [2].
The NINCDS-ADRDA criteria [3] are currently
applied in diagnostic guidelines [4,5] to determine AD
aetiology. Scientific knowledge, advanced imaging tech-
niques and cerebrospinal fluid analyses have evolved
since the publication of these criteria in 1984. This has
led to much debate and the proposition of new clinical
and research criteria to enhance diagnostic accuracy,
even at the stage of early clinical symptoms [6-10].
These criteria distinguish between the AD pathophysio-
logical process and the clinically observable syndrome to
enable determination of AD in a pre-dementia state; e.g.
mild cognitive impairment (MCI). In the end the criteria
are meant to support therapy decision making (when
effective treatments are available) or to determine the
likelihood of cognitive and functional progression to a
more severe disease state. Emerging biomarkers are
attributed a more prominent role in the diagnostic cri-
teria; amyloid β42, total tau and phosphorylated-tau in
the cerebrospinal fluid (CSF), amyloid tracer uptake and
fluorodeoxyglucose (FDG) in positron emission tomog-
raphy (PET), hippocampal volume and medial temporal
atrophy in structural magnetic resonance imaging (MRI)
and single photon emission tomography (SPECT) per-
fusion imaging. However, validation of the criteria is
needed before adoption of the proposed role of new
biomarkers in clinical practice [9].
The ultimate goal of diagnostic testing is to guide dis-
ease management in order to improve patient outcomes
and patient well-being. Tests that lack this potential
should be regarded obsolete [11,12]. This has raised
an urgent need for health technology assessment to
address the direct, intended consequences of techno-
logies as well as the indirect, unintended consequences
for the evaluation of the value of diagnostic strategies
including biomarker for AD compared to current clin-
ical practice. Evidence is needed to support decision
makers on the adoption of new diagnostic tests in
clinical practice to enable efficient allocation of health
care resources.
Study aim
The general aim of the study is to assess the clinical and
economic value of current, emerging and novel (to
be developed) techniques for an early diagnosis of ADand related disorders. In this paper the methodology
is described.
The research goals are:
1. To assess the diagnostic test accuracy of the current
clinical standard diagnostic work-up and emerging
diagnostic biomarkers in MRI, PET and CSF
2. To assess costs and effects for the follow-up
period to perform a cost-consequence and
cost-effectiveness analysis
3. To develop a preliminary economic model to
assess the uncertainty surrounding long-term
cost-effectiveness of diagnostic strategies
Methods/design
Study design
A cohort design was chosen because an assessment of
test combinations within a randomized controlled trial
would require the evaluation of many diagnostic strat-
egies for which the number of subjects needed would
exponentially increase [13]. To determine the diagnostic
value of emerging biomarkers for AD and related disor-
ders both a clinical diagnosis and diagnosis based on
emerging biomarkers (index tests) are compared with a
reference diagnosis. Due to limited ability of biopsy
(which is unethical) or autopsy (which requires follow
up until death) a two-year follow up of the clinical
course is used as a proxy to obtain information on the
state of the disease at baseline; so-called delayed-type
cross-sectional accuracy study design [12]. Four aca-
demic memory clinics (Leiden University Medical
Centre, Maastricht University Medical Centre, Radboud
University Nijmegen Medical Centre and VU University
Medical Centre) specialized in the diagnosis and treat-
ment of memory disorders participate in the study. Two
memory clinics are settled within a department of geria-
trics, one within neurology and one within psychiatry.
The study is performed within the framework of
CTMM, the Center for Translational Molecular Medi-
cine (www.ctmm.nl), a Dutch public-private partnership;
project LeARN (grant 02 N-101).
Subjects
For the study, 241 consecutive patients of the participating
memory clinics who were suspected of having a primary
neurodegenerative disease were included for participating
in the study from October 2009 to May 2011; this
included all patients with subjective and/or objective
memory complaints. Eligibility criteria were chosen to
represent the current clinical situation and enable general-
isability to clinical practice (see Table 1). Informed consent
was obtained from both the patient and the in-
formal caregiver. Gender, age and reason for refusal were
obtained for patients unwilling to participate.
Table 1 Eligibility criteria for subject selection
Inclusion criteria
- All new consecutive patients of the participating memory clinics who
are suspected of having a primary neurodegenerative disease
- Mini-Mental State Examination: ≥ 20
- Clinical Dementia Rating: 0 – 1
- Availability of a reliable informer or proxy (who visits or contacts the
patient at least once a week)
Exclusion criteria
- Normal Pressure Hydrocephalus, Huntington’s disease
- Less than two years ago a transient ischaemic attack (TIA) or cerebral
vascular accident (CVA) or TIA/CVA followed (within three months) by
cognitive impairment
- Psychiatric history (schizophrenia, bipolar disorder or psychotic
problems (not otherwise specified), less than 12 months ago)
- Major Depression according to the DSM-IV, less than
12 months ago
- Cognitive problems due to excessive alcohol use (based on clinical
judgement)
- Brain tumour, epilepsy, encephalitis
- Probably not available for follow-up
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Each centre collects a minimum dataset of clinical infor-
mation based upon the dataset protocol used for The
String of Pearls Initiative – Pearl Neurodegenerative
Diseases (www.string-of-pearls.org), cost data and data
on emerging biomarkers. Table 2 provides an overview
of all patient and informal caregiver assessments. Assess-
ments take place at baseline and at 12 and 24 months
follow up during a visit (from both patient and informal
caregiver) to the memory clinic. Furthermore, several
questionnaires were composed in a booklet to measure
resource consumption and quality of life. This is filled
out by the informal caregiver at baseline, 3, 12 and
24 months.
Clinical data
Demographic and medical information is retrieved from
an open interview with both patient and informal care-
giver and physical examination by a clinician.
The Mini Mental State Examination is used to detect
cognitive impairment, to assess its severity and to moni-
tor cognitive changes over time [14]. The Clinical
Dementia Rating scale (CDR) [15,16] provides a global
rating of dementia severity. The Geriatric Depression
Scale-15 [17] is applied to detect depression. Patient’s
behavioural and psychological problems are measured
by the Neuropsychiatric Inventory (NPI) [18]. The Dis-
ability assessment for Dementia (DAD) is assessed to
evaluate basic and instrumental activities in daily activ-
ities [19]. The information of both the NPI and DAD is
obtained from a caregiver familiar with the patient’sbehaviour by means of a semi structured interview.
Caregiver’s burden of care is assessed using the disease
specific Sense of Competence Questionnaire (SoCQ)
[20,21].
Neuroimaging markers include medial temporal lobe
atrophy measurements and white matter lesions which
are qualitatively scored based on 3 T MRI scan images.
Neuropsychological examination consists of a standar-
dized battery of cognitive tests performed by a (neuro)
psychologist. Tests include Rey’s Verbal Learning Test
[22,23], Visual Association Test [24], and Digit-Span [25]
to assess memory; Letter Digit Substitution Test [26]
to assess mental processing rate; and Stroop Color-
Word Test [27] and Trail Making Test [28,29] to assess
attention, concentration and interference. Raw scores
were converted to z-scores, adjusting for age, education
and gender.Quality of life data
Patient’s generic quality of life is measured by the EQ-
5D instrument. It was developed and validated in a
number of European countries including the Netherlands
[30-32] and it has been validated in patients with demen-
tia [33,34]. The EQ-5D describes health status according
to five three-level dimensions, which yields 243 potential
combinations of health states. Each combination leads to
a utility score by means of an additive function derived
from the UK general population [35,36].
Patient disease specific quality of life is measured by
the validated Quality of Life – Alzheimer’s Disease scale
(QoL–AD) [37,38]. It has 13 items covering the domains
of physical health, energy, mood, living situation, mem-
ory, family, marriage, friends, self as a whole, ability to
do chores around the house, ability to do things for fun,
money, and life as a whole. Scale scores range from 13
to 52 with higher scores indicating greater QoL. An
improvement of 3 points on the QoL-AD is judged as
clinically relevant as this indicates a change of well-being
on one of the domains from very poor to excellent [39].
Patient EQ-5D is assessed by the patient during the
visit to the memory clinic. Furthermore, the informal
caregiver judges the EQ-5D and QoL-AD for the situ-
ation of the patient and for his/her own situation and
fills this out in the booklet of questionnaires.
Care-related quality of life of informal caregivers
is assessed by the CarerQol[40]. It combines seven
important burden dimensions with a valuation com-
ponent (a visual analogue scale (VAS)) for happiness.
The seven burden dimensions are 1) fulfilment; 2) rela-
tional problems; 3) mental problems; 4) problems with
daily activities; 5) financial problems; 6) support; and
7) physical problems. The CarerQol-VAS ranges from 0
(“completely unhappy”) to 100 (“completely happy”)
Table 2 Overview of patient and informal caregiver assessments at baseline and follow-up
Outcome measure Operationalization/type of instrument B T3 T12 T24
Clinical data
Demographic data History taking P P P
Cognitive impairment Mini-mental State Examination P P P
Dementia severity Clinical Dementia Rating P P P
Functional disability Disability Assessment for Dementia P P P
Neurological and physical examination Neurological assessment and evaluation
of co-morbidities
P P P
Neuropsychiatric problems Neuropsychiatric Inventory P P P
Depression Geriatric Depression Scale 15 P P P
Cerebral atrophy and white matter lesions Structural MRI (T1-weighted, T2-weighted
and FLAIR)
P
Neuropsychological Assessment Rey’s Verbal Learning Test, Visual
Association Test, Digit-Span,
Letter Digit Substitution Test,
Stroop Color-Word Test, Trail Making Test
P P P
Quality of life data
Patient generic quality of life EQ-5D I*/P I* I*/P I*/P
Patient disease specific quality of life* QoL-AD I * I * I * I *
Caregiver generic quality of life* EQ-5D I I I I
Caregiver disease specific quality of life* QoL-AD I I I I
Caregiver burden* Sense Of Competence I I I I
Care-related quality of life* Carer Quality of Life I I I I
Cost data*
Resource utilization and caregiver time RUD-Lite I I I I
Work productivity and absence Productivity and Disease Questionnaire I I I I
Consequences of informal caregiving
on paid or unpaid work
Health and Labour Questionnaire I I I I
Other resource use I I I I
Emerging biomarker data
Functional connectivity Resting state functional MRI P
White matter integrity Diffusion tensor imaging P
Hippocampal volume Structural MRI P
Glucose metabolism Fluorodeoxyglucose PET† P
Amyloid plaque deposition Pittsburgh compound B PET†, CSF Aβ1-42 P
Tau CSF total tau, CSF phosphorylated tau P
*These items were assessed by the informal caregiver by means of a booklet in which several questionnaires were composed for resource consumption and
quality of life.
†Data on this item are only collected at the memory clinic of the VU University Medical Centre Amsterdam.
Abbreviations: B, Baseline; FLAIR, Fluid attenuation inversion recovery; I, Information retrieved from informal caregiver; MRI, Magnetic Resonance Imaging;
P, Information retrieved from patient; PET, positron emission tomography; QoL-AD, Quality of Life Alzheimer’s Disease scale; RUD-Lite, Resource Utilization
In Dementia; T3, 3 month follow-up measurement; T12, 12 month follow-up measurement; T24, 24 month follow-up measurement.
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neous caregivers.
Cost data
Cost data are retrieved by the composed booklet of
questionnaires. Patient resource utilization and caregiver
time, which often contains productivity losses, are
assessed by means of the short version of the ResourceUtilization in Dementia-questionnaire (RUD-lite). This
instrument has been validated and proved to register
over 95% of the costs involved in AD-care [41]. Work
status, income, and productivity losses of both the
patient and caregiver are assessed by the adjusted PRO-
DISQ (PROductivity and DISease Questionnaire) [42].
The consequences of informal caregiving on paid or
unpaid work are assessed by the Health and Labour
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whether one was ill, ill by caregiving or not ill [43]. Add-
itional questions are asked referring to the number of
visits to various health care professionals, resources or
aids that are bought and other out-of-pocket costs.
Emerging biomarker data
Biomarkers can be divided into two categories, one
reflecting the presence of beta-amyloid protein (Aβ) and
one reflecting neuronal degeneration or injury. A patho-
logical cascade is hypothesized in which basically Aβ
markers become abnormal first, followed by neuronal
injury [9,44].
The biomarkers included in this project are outlined
in Table 3. CSF is collected and Amyloid β42, total tau
and phosphorylated-tau are analyzed using a standar-
dized quantitative method. FDG uptake and Pittsburgh
compound B binding (PiB) on PET are both qualitatively
rated by a radiologist and quantitatively analyzed by
standardized methods. Whole brain and hippocampal
volume, white matter integrity and functional connectiv-
ity derived by MR imaging are quantitatively analyzed by
a researcher. These tests are not part of the current rou-
tine clinical diagnostic procedure. They are judged and
analyzed independently and blindly. The outcome of
each test is dichotomous or continuous, both for AD
aetiology and progression of cognitive decline.
Baseline clinical diagnosis and reference diagnosis
Current clinical practice diagnosis is reflected by a con-
sensus procedure among experts using baseline clinical
information only, excluding any information of emerging
biomarkers to prevent underestimating their accuracy.
The reference diagnosis is also determined by a con-
sensus procedure among experts based on clinical infor-
mation on the course of symptoms over a two-year time
period and applying the core clinical criteria for the
diagnosis of dementia due to AD [8] and core clinicalTable 3 Included biomarkers in the project categorized
by reflecting Aβ or neuronal injury
Technique Aβ accumulation Neuronal dysfunction
CSF Amyloid β42 in the CSF total tau and phosphorylated-tau
in CSF
PET amyloid tracer uptake
in PET
fluorodeoxyglucose PET
MRI White matter integrity (DTI)
Functional connectivity (rsfMRI)
Whole brain volume
Hippocampal volume
Abbreviations: Aβ, beta-amyloid protein; CSF, cerebrospinal fluid; DTI,
diffusion tensor imaging; MRI, magnetic resonance imaging; PET,
positron emission tomography; rsfMRI, resting state functional magnetic
resonance imaging.criteria for the diagnosis of MCI due to AD [7]. Experts
are kept blind for any information of the emerging mar-
kers under evaluation. Evaluating all cases by expert
panel discussion meetings is highly time consuming.
Therefore, first expert raters will assess all cases by
means of an internet based form and if consensus is not
reached the case will be discussed by a panel discussion
meeting. The consensus diagnosis during the expert
panel meetings is based on a modified Delphi method in
which face-to-face discussions are held [45,46].
Analyses
Several diagnostic procedures based on current practice
and emerging biomarker information (index tests) are
compared to the reference diagnosis. First, AD aetiology
based on the core clinical criteria [7,8] is evaluated. This
is reflected by the baseline diagnosis as determined by
the consensus procedure. No information of any emer-
ging biomarker is included. Second, AD aetiology based
on the research criteria as established by the National
institute on aging and the Alzheimer’s Association are
evaluated [9]. At last, several explorative decision rules
are applied including clinical information and biomarker
information to determine AD aetiology and suspected
progression of cognitive decline within two years.
Research goal 1: Diagnostic test accuracy
Diagnostic test accuracy is determined by relating index
test results to the reference diagnosis (reference test).
All diagnoses consist of a dichotomous outcome value
on underlying pathology of the clinical syndrome and on
(expected) progression of cognitive decline within two
years. Separately for aetiology and progression of cogni-
tive decline each index test result for each case is indi-
cated as either true positive, true negative, false positive
or false negative based on the reference diagnosis (refer-
ence test). This enables the calculation of accuracy esti-
mates: sensitivity, specificity, positive predictive value,
negative predictive value, likelihood ratio and (an in-
crease of) the Area Under the Curve of a Receiver Oper-
ating Characteristic curve.
Finally, novel innovative diagnostic tests are developed
during the course of this study by other cooperating
researchers for which proof of principle does not yet
exist. These tests will be evaluated as soon as evaluation
in clinical subjects is possible. To assess diagnostic
accuracy the tests will be applied in subgroups of the
cohort retrospectively (for CSF samples) or using a
case–control design.
Research goal 2: Cost-consequence and cost-effectiveness
analysis
A cost-consequence analysis is performed listing all rele-
vant costs and effects without aggregating it into a ratio
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particular interest to include in an economic analysis.
Average costs and consequences of the whole cohort are
compared with the subgroup of patients who have
received a correct diagnosis according to the reference
test. This enables the comparison of the current diag-
nostic practice costs and effects and the costs and effects
of an ideal situation (a costless diagnostic test with 100%
accuracy). The difference indicates the maximum pos-
sible achievable benefit of new biomarkers for AD and
related disorders in terms of costs and health effects.
Furthermore, a cost-effectiveness analysis is performed
comparing current practice with diagnostic procedures
that include emerging biomarkers. The change in costs
is compared to the change in diagnostic accuracy to
obtain a cost-effectiveness ratio in terms of costs per
correctly diagnosed patient.
Research goal 3: Decision analytic model
Finally a decision analytic model is built which provides
a framework combining available evidence from different
resources among which (accuracy) results from the
study, literature and expert opinion. A decision analytic
model can be defined as a set of mathematical relation-
ships that form a structure reflecting the natural pro-
gression of a disease. By simulating patients or fractions
of a population, these models enable the estimation of the
likelihood of each consequence and its corresponding
costs and effects [48]. It is applied to evaluate the short-
term cost-effectiveness in terms of cost per correct diag-
nosis and long-term cost-utility in terms of cost per qual-
ity adjusted life year gained of diagnostic strategies under
evaluation. Utility scores will be used to calculate Quality
Adjusted Life Years (QALY). Patients who pass away
during the year covered by the evaluation will be given a
utility score of zero from the exact time of death. QALYs
will be derived using the trapezium rule. A societal view-
point will be adopted including the evaluation of all rele-
vant costs and effects to calculate the societal benefits.
The cohort design facilitates the evaluation of many
different diagnostic procedures by varying the place of a
new diagnostic marker in the clinical pathway. Each pro-
cedure generates specific proportions of correct or in-
correct diagnoses. Average costs and effects of correct
and incorrect diagnoses are applied to calculate the total
costs and effects of each procedure.
Sensitivity analysis will be performed taking into
account both first order uncertainty regarding varia-
tion between patients in a homogeneous group and sec-
ond order uncertainty regarding the true value of the
parameters included in the model. This also enables
the evaluation of an earlier diagnosis, different test
sequences and the effect of possible new disease modify-
ing drug treatments.Sample size and missing data
A telephone interview is performed for patients who
refuse follow-up assessments to determine the reason for
refusal, possible cognitive decline and interference with
daily activities, and to assess the CDR. Incomplete data
will be imputed by means of a regression model. Complete
missing data or data missing covariates will be imputed
using Rubin’s multiple imputation (MI) procedure.
Sample size is based on an 80% accuracy of current
clinical practice to determine correct aetiology [4] and
70% in non-demented patients [49]. Applying a type I
error (α= 5%), type II error (β= 80%), drop-out rate of
10% and minimum clinically relevant difference of 10%
accuracy increase requires 219 patients to be included
in the study.
Contrary to clinical studies, economic evaluations are
not based on testing hypotheses. Their goal is to assess
decision uncertainty. Therefore, economic evaluations
are restricted to the estimation of the uncertainty sur-
rounding cost-effectiveness (expressed in a statistical
confidence interval). Within this Bayesian framework,
classical inference (and therewith a power analysis) is
irrelevant [50].
Ethical considerations
According to the medical ethics committee “Med-
ischEthischeCommissieazM/UM” the research protocol
complies with the Declaration of Helsinki (October
2008, www.wma.net, ref.nr.: MEC 09-3-038) and with
the Medical Research Involving Human Subjects Act
and codes on ‘good use’ of clinical data and biological
samples as developed by the Dutch Federation of Med-
ical Scientific Societies.
Discussion
This research protocol describes the methods used to
assess the clinical and economic value of new diagnostic
approaches for the diagnosis of AD. A delayed-type
cross-sectional accuracy study design is chosen because
a randomized clinical trial comes with ethical issues,
long follow-up time and limited power. Two hundred
forty one consecutive patients suspected of having a
primary neurodegenerative disease are followed up for
two years and a reference diagnosis is determined by an
independent consensus expert panel. Eligibility criteria
are chosen to maximally reflect a patient cohort within
clinical practice.
Several other multi-centre trials study the relative
value of new biomarkers for early evaluation of AD and
related disorders. The Alzheimer’s Disease Neuroima-
ging Initiative (ADNI) in North America is aimed to
identify neuroimaging measures and biomarkers asso-
ciated with cognitive and functional changes in healthy
elderly subjects and in subjects who have MCI and AD
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Guidelines and Clinical Criteria for Predementia AD’
(DESCRIPA) study is aimed to develop screening guide-
lines for predementia AD in the general population [52].
Both include markers in PET, MR imaging and CSF. The
uniqueness of this study is the assessment of resource
utilization and quality of life to enable an economic
evaluation. Furthermore, the decision analytic model
enables the evaluation of the optimal diagnostic strategy
and the evaluation of diagnostic techniques to be devel-
oped during the study in sub-cohorts of the study popu-
lation. At last, without a disease modifying treatment,
the added value of biomarkers is uncertain. Therefore,
the availability of such treatment is explored in the sen-
sitivity analysis.
The study has some limitations. It focuses on applying
new tests for diagnostic or prognostic goals. Screening
and treatment monitoring are outside the scope of this
study. A follow-up period of two years was taken as
a compromise to maximise the time for the disease to
express symptoms of progression (to prevent false nega-
tive reference diagnoses) and to minimize the time to
prevent the start of a new disease episode after the base-
line assessment (to prevent false positive reference diag-
nosis). It may take up to 10 years before all symptoms
of dementia come to expression in subjects with AD
pathology [53].
The study results are generalizable to a population of
patients who are referred to a memory clinic of a univer-
sity medical centre due to their memory problems.
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